



HAL
open science

Activity of doripenem against extended-spectrum β -lactamase-producing Enterobacteriaceae and isolates

C. Betriu, M. Gómez, F. López-Fabal, E. Culebras, I. Rodríguez-Avial, J. J. Picazo

► To cite this version:

C. Betriu, M. Gómez, F. López-Fabal, E. Culebras, I. Rodríguez-Avial, et al.. Activity of doripenem against extended-spectrum β -lactamase-producing Enterobacteriaceae and isolates. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29 (9), pp.1179-1181. 10.1007/s10096-010-0974-3 . hal-00598098

HAL Id: hal-00598098

<https://hal.science/hal-00598098>

Submitted on 4 Jun 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Editorial Manager(tm) for European Journal of Clinical Microbiology & Infectious
Diseases
Manuscript Draft

Manuscript Number: EJCMIID-D-10-00134R1

Title: ACTIVITY OF DORIPENEM AGAINST EXTENDED-SPECTRUM β -LACTAMASE-PRODUCING
ENTEROBACTERIACEAE AND *Pseudomonas aeruginosa* ISOLATES

Article Type: Brief Report

Keywords: Doripenem; Susceptibility; Extended-spectrum β -lactamase-producing Enterobacteriaceae;
Pseudomonas aeruginosa

Corresponding Author: Dr. Carmen Betriu, PhD

Corresponding Author's Institution: Hospital Clínico San Carlos

First Author: Carmen Betriu

Order of Authors: Carmen Betriu; María Gómez; Fátima López-Fabal; Esther Culebras; Iciar Rodríguez-
Avial; Juan J Picazo

Abstract: The in vitro activity of doripenem was evaluated against a recent collection of extended-spectrum β -lactamase (ESBL)-producing Enterobacteriaceae and *Pseudomonas aeruginosa* isolates (201 ESBL-producing Enterobacteriaceae [153 *Escherichia coli* and 48 *Klebsiella pneumoniae*] and 201 *P. aeruginosa*. Comparator agents included amikacin, tobramycin, ciprofloxacin, cefepime, cefotaxime, piperacillin-tazobactam, imipenem, and meropenem. Both doripenem and meropenem inhibited 100% of the ESBL-producing Enterobacteriaceae at $\leq 0.5 \mu\text{g/mL}$. For these isolates, the MIC₉₀ of doripenem (0.12 $\mu\text{g/mL}$) was 4-fold lower than that of imipenem (0.5 $\mu\text{g/mL}$). Against *P. aeruginosa*, the MIC₉₀ of doripenem and meropenem was 2 $\mu\text{g/mL}$, 4-fold lower than that of imipenem (8 $\mu\text{g/mL}$). At an MIC of $\leq 2 \mu\text{g/mL}$, doripenem, meropenem, and imipenem inhibited 90.5%, 89.6%, and 82.1% of *P. aeruginosa* isolates, respectively. Doripenem maintained activity against imipenem-nonsusceptible isolates of *P. aeruginosa*; at an MIC of $\leq 4 \mu\text{g/mL}$, it inhibited 15 of the 25 isolates with MICs for imipenem of $>4 \mu\text{g/mL}$. Doripenem is active against ESBL-producing Enterobacteriaceae and *P. aeruginosa* isolates. Its activity is similar to that of meropenem and slightly better than that of imipenem. The results of this study suggest that doripenem could be an alternative therapeutic agent for infections caused by these organisms.

May 10, 2009

Dr. Alex van Belkum
Editor-in-Chief
European Journal of Clinical Microbiology & Infectious Diseases

Ref.: Ms. No. EJCMIID-D-10-00134

Dear Dr. van Belkum,

Thank you for your e-mail dated April 30. We enclose a revised version of the manuscript.

Following the recommendations of the reviewer, we have addressed the following points:

1. MIC interpretations were made using EUCAST breakpoint criteria. We have therefore modified Table 1 (% Resistant strains) in accordance with these data. As we used the EUCAST breakpoints in Table 1, we have added a new comment in the text regarding the FDA susceptibility criteria applied to doripenem for Enterobacteriaceae and *P. aeruginosa* isolates. We have provided two references (nos. 11 and 12 in the revised manuscript) for the breakpoint concentrations.
2. A new Table showing the distribution of doripenem MICs for the organisms tested has been added.
3. The period during which the strains were isolated has been included in the new version of the manuscript.
4. When reviewing the original manuscript, we realized that the term "cefepime" (page 4, line 7) was incorrect. This has been changed in the new version to "ceftazidime".
5. The Etest ESBL strips used for ESBL confirmatory test have been indicated in the revised manuscript. In the Results section we also indicate that all tested Enterobacteriaceae were confirmed to be ESBL-producing strains.
6. As requested, we have omitted the term "excellent" from the description of the activity of doripenem.
7. On Table 1, mg/L has been changed to µg/mL, as it appears in the rest of the manuscript.

8. We used two decimal places when describing MIC values for concentrations ≥ 0.03 .

We hope that you will now find the manuscript suitable for publication in the Journal and we thank the reviewer for the suggestions.

Yours sincerely,

Carmen Betriu

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

**ACTIVITY OF DORIPENEM AGAINST EXTENDED-SPECTRUM β -
LACTAMASE-PRODUCING ENTEROBACTERIACEAE AND
Pseudomonas aeruginosa ISOLATES**

C. BETRIU, M. GÓMEZ, F. LÓPEZ, E. CULEBRAS, I. RODRÍGUEZ-AVIAL, J.

J. PICAZO

**Servicio de Microbiología Clínica, Hospital Clínico San Carlos, Madrid,
Spain**

Corresponding autor: C. Betriu.

Servicio de Microbiología Clínica, Hospital Clínico San Carlos,

Plaza Cristo Rey s/n,

28040 Madrid, Spain

e-mail: cbetriu.hcsc@salud.madrid.org

Abstract

The in vitro activity of doripenem was evaluated against a recent collection of extended-spectrum β -lactamase (ESBL)-producing Enterobacteriaceae and *Pseudomonas aeruginosa* isolates (201 ESBL-producing Enterobacteriaceae [153 *Escherichia coli* and 48 *Klebsiella pneumoniae*] and 201 *P. aeruginosa*). Comparator agents included amikacin, tobramycin, ciprofloxacin, cefepime, cefotaxime, piperacillin-tazobactam, imipenem, and meropenem. Both doripenem and meropenem inhibited 100% of the ESBL-producing Enterobacteriaceae at ≤ 0.5 $\mu\text{g/mL}$. For these isolates, the MIC₉₀ of doripenem (0.12 $\mu\text{g/mL}$) was 4-fold lower than that of imipenem (0.5 $\mu\text{g/mL}$). Against *P. aeruginosa*, the MIC₉₀ of doripenem and meropenem was 2 $\mu\text{g/mL}$, 4-fold lower than that of imipenem (8 $\mu\text{g/mL}$). At an MIC of ≤ 2 $\mu\text{g/mL}$, doripenem, meropenem, and imipenem inhibited 90.5%, 89.6%, and 82.1% of *P. aeruginosa* isolates, respectively. Doripenem maintained activity against imipenem-nonsusceptible isolates of *P. aeruginosa*; at an MIC of ≤ 4 $\mu\text{g/mL}$, it inhibited 15 of the 25 isolates with MICs for imipenem of >4 $\mu\text{g/mL}$. Doripenem is active against ESBL-producing Enterobacteriaceae and *P. aeruginosa* isolates. Its activity is similar to that of meropenem and slightly better than that of imipenem. The results of this study suggest that doripenem could be an alternative therapeutic agent for infections caused by these organisms.

Keywords: Doripenem, Susceptibility, Extended-spectrum β -lactamase-producing Enterobacteriaceae, *Pseudomonas aeruginosa*

Introduction

The incidence of extended-spectrum- β -lactamase (ESBL)-producing Enterobacteriaceae has been increasing worldwide to the extent that it is now an important cause of both hospital- and community-acquired infections [1]. *Pseudomonas aeruginosa* remains a major pathogen. Its intrinsic resistance to multiple antibiotics and its capability to develop mutational resistance to commonly used antimicrobials make treatment of this entity challenging [2, 3].

Doripenem is a new parenteral 1- β -methyl carbapenem with broad activity against gram-positive bacteria, Enterobacteriaceae, anaerobes, and non-fermentative bacilli such as *P. aeruginosa* [4-8]. Like other carbapenems, doripenem is stable against human renal dehydropeptidases and to many β -lactamases. The purpose of this study was to evaluate the in vitro activity of doripenem and comparator agents against a recent collection of ESBL-producing Enterobacteriaceae and *P. aeruginosa* isolates.

Materials and methods

A total of 402 isolates collected from 2006 to 2008 were processed. Identification was by ID 32 GN (bioMérieux, Marcy l'Etoile, France). The isolates tested comprised 201 ESBL-producing Enterobacteriaceae (153 *Escherichia coli* and 48 *Klebsiella pneumoniae*) and 201 *P. aeruginosa*. *E. coli* ATCC 25922, *E. coli* ATCC 35218, and *P. aeruginosa* ATCC 27853 were used as quality control strains

Isolates were tested using the reference broth microdilution method of the Clinical Laboratory Standards Institute (CLSI) [9]. Cation-adjusted Mueller-Hinton broth was used. The antibiotics evaluated were doripenem, tobramycin,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ciprofloxacin, cefepime, cefotaxime, ceftazidime, piperacillin-tazobactam, imipenem, and meropenem. According to the CLSI [10] criteria, *E. coli* and *Klebsiella* spp. isolates with increased MIC results (≥ 2 $\mu\text{g/mL}$) for cefotaxime and/or ceftazidime were suspected of being ESBL-producing isolates. Phenotypic confirmation of these strains was performed using Etest ESBL strips (cefotaxime/cefotaxime+clavulanic acid, and ceftazidime/ceftazidime+clavulanic acid) (bioMérieux, Marcy l'Etoile, France). Isolates were defined as susceptible or resistant to antibiotics in accordance with the breakpoints approved by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [11]

Results and discussion

Table 1 summarizes the MICs of doripenem and the comparator agents against the bacterial isolates included in the study. The phenotypic confirmatory test confirmed all Enterobacteriaceae isolates to be ESBL-producers. Doripenem showed activity against the ESBL-producing isolates tested. The doripenem MICs at which 50% and 90% of the isolates were inhibited (MIC_{50} and MIC_{90}) were 0.06 $\mu\text{g/mL}$ and 0.12 $\mu\text{g/mL}$, respectively. Both doripenem and meropenem inhibited 100% of the ESBL-producing Enterobacteriaceae at ≤ 0.5 mg/L. Most of these organisms (96%) were resistant to ciprofloxacin. The MIC_{90} of doripenem (0.12 $\mu\text{g/mL}$) was 4-fold lower than that of imipenem (0.5 $\mu\text{g/mL}$) for the ESBL-producing Enterobacteriaceae.

Against *P. aeruginosa*, the MIC_{90} of doripenem and meropenem were both 2 $\mu\text{g/mL}$, 4-fold lower than that of imipenem (8 $\mu\text{g/mL}$). At a concentration of ≤ 2 $\mu\text{g/mL}$, doripenem, meropenem, and imipenem inhibited 90.5%, 89.6%, and 82.1% of *P. aeruginosa* isolates, respectively. Other agents with similar

1 activity to doripenem against *P. aeruginosa* included tobramycin, cefepime, and
2 amikacin (90% to 95% of susceptibility). Doripenem maintained its activity
3 against imipenem-nonsusceptible isolates of *P. aeruginosa*. At a concentration
4 of ≤ 4 $\mu\text{g/mL}$, doripenem inhibited 15 of the 25 isolates with MICs for imipenem
5 of ≤ 4 $\mu\text{g/mL}$, doripenem inhibited 15 of the 25 isolates with MICs for imipenem
6 of > 4 $\mu\text{g/mL}$.
7
8
9

10
11 The distribution of doripenem MICs against the organisms tested is
12 indicated in Table 2. According to the doripenem breakpoints approved by the
13 US Food and Drug Administration (FDA) (susceptible, ≤ 0.5 $\mu\text{g/mL}$ for
14 Enterobacteriaceae, and ≤ 2 $\mu\text{g/mL}$ for *P. aeruginosa*) [12], all of the ESBL-
15 producing Enterobacteriaceae and 90.5% of the *P. aeruginosa* isolates were
16 susceptible to doripenem.
17
18
19
20
21
22
23
24
25

26 In this study, doripenem is very active against ESBL-producing
27 Enterobacteriaceae and *P. aeruginosa* isolates. Its activity is similar to that of
28 meropenem and slightly better than that of imipenem. Our results are consistent
29 with those of other investigators [4,7].
30
31
32
33
34
35

36 Doripenem is well tolerated and less associated with the adverse effects
37 when compared with imipenem or meropenem [13,14]. It also showed less
38 potential to select resistant mutants than meropenem [15, 16]. As has been
39 described in previous studies [4,7,17], we also found some *P. aeruginosa*
40 isolates that were resistant to imipenem and meropenem with low MICs for
41 doripenem. These favourable characteristics, together with the potent in vitro
42 activity observed in this study and by other authors [4-7], suggest that
43 doripenem could be a therapeutic alternative against infections caused by these
44 multidrug-resistant organisms.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgments

These data were presented, in part, at the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, 2009 (E-172).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- 1 Pitout JD, Nordmann P, Laupland KB, Poirel L (2005) Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. *J Antimicrob Chemother* 56:52-59.
- 2 Livermore DM (2002) Multiple mechanisms of antimicrobial resistance in *Pseudomonas aeruginosa*: our worst nightmare? *Clin Infect Dis* 34:634-640.
- 3 Quinn JP (1998) Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. *Clin Infect Dis* 27 Suppl 1:S117-S124.
- 4 Castanheira M, Jones RN, Livermore DM (2009) Antimicrobial activities of doripenem and other carbapenems against *Pseudomonas aeruginosa*, other nonfermentative bacilli, and *Aeromonas* spp. *Diagn Microbiol Infect Dis* 63:426-433.
- 5 Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA (2004) In vitro antimicrobial activity of doripenem, a new carbapenem. *Antimicrob Agents Chemother* 48:1384-496.
- 6 Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS (2009) Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. *Diagn Microbiol Infect Dis* 63:415-125.
- 7 Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF (2008) In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical

isolates from the United States. Antimicrob Agents Chemother 52:4388-4399.

- 1
2
3
4
5 8 Wexler HM, Engel AE, Glass D, Li C (2005) In vitro activities of
6
7 doripenem and comparator agents against 364 anaerobic clinical isolates.
8
9 Antimicrob Agents Chemother 49:4413-4417.
10
11
12 9 Clinical and Laboratory Standards Institute (CLSI) (2009) Methods for
13
14 dilution antimicrobial susceptibility tests for bacteria that grow aerobically.
15
16 Approved standard, 8th edition. M7-A8, vol. 29, no. 2. CLSI, Wayne, PA:
17
18
19 10 Clinical and Laboratory Standards Institute (CLSI) (2009) Performance
20
21 standards for antimicrobial susceptibility testing. 19th informational
22
23 supplement. M100-S19, vol 29, no. 3. CLSI, Wayne, PA:
24
25
26
27 11 The European Committee on Antimicrobial Susceptibility Testing
28
29 (EUCAST) (2010). Clinical breakpoints. European Society for Clinical
30
31 Microbiology and Infectious Diseases. Available online at:
32
33 http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk-
34
35 [test-documents/EUCAST_breakpoints_v1.1.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk-test-documents/EUCAST_breakpoints_v1.1.pdf). April 2010.
36
37
38
39 12 Doribax product package insert (2009). Ortho-McNeil-Janssen
40
41 Pharmaceuticals, Inc. Raritan, NJ. Available online at:
42
43 <http://www.doribax.com/doribax/shared/pi/doribax.pdf#zoom=100>.
44
45 Revised 11/2009.
46
47
48 13 Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K (2006)
49
50 Absence of convulsive liability of doripenem, a new carbapenem
51
52 antibiotic, in comparison with beta-lactam antibiotics. Toxicology
53
54 222:114-124.
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 14 Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I (2008) Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. *Clin Ther* 30:868-883.
- 15 Mushtaq S, Ge Y, Livermore DM (2004) Doripenem versus *Pseudomonas aeruginosa* in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. *Antimicrob Agents Chemother* 48:3086-3092.
- 16 Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y (2006) Potency of carbapenems for the prevention of carbapenem-resistant mutants of *Pseudomonas aeruginosa*: the high potency of a new carbapenem doripenem. *J Antibiot (Tokyo)* 59:220-228.
- 17 Fujimura T, Anan N, Sugimori G, Watanabe T, Jinushi Y, Yoshida I, Yamano Y (2009) Susceptibility of *Pseudomonas aeruginosa* clinical isolates in Japan to doripenem and other antipseudomonal agents. *Int J Antimicrob Agents* 34:523-528.

Table 1. In vitro activities of doripenem and other antimicrobial agents against extended-spectrum- β -lactamase (ESBL)-producing Enterobacteriaceae and *Pseudomonas aeruginosa* isolates.

Organism (no. of isolates)	Antimicrobial agent	MIC ($\mu\text{g/mL}$)			% Resistant strains ^b
		Range	50%	90%	
(ESBL)-producing					
Enterobacteriaceae ^a					
(201)	Doripenem	0.015 - 0.5	0.06	0.125	0
	Imipenem	≤ 0.25 - 2	≤ 0.25	0.5	0
	Meropenem	≤ 0.05	≤ 0.5	≤ 0.5	0
	Piperacillin-tazobactam	≤ 8 - >64	≤ 8	>64	27.4
	Cefotaxime	≤ 1 - >32	32	>32	93.0
	Ceftazidime	≤ 0.25 - >16	8	>16	57.2
	Cefepime	≤ 1 - >16	8	>16	53.2
	Amikacin	≤ 4 - >32	≤ 4	16	5.0
	Tobramycin	≤ 2 - >8	8	>8	52.5
	Ciprofloxacin	≤ 0.25 - >2	>2	>2	96.0.
<i>P. aeruginosa</i> (201)					
(201)	Doripenem	0.06 - >8	0.5	2	5.0
	Imipenem	≤ 0.25 - >8	1	8	9.5
	Meropenem	≤ 0.5 - >8	≤ 0.5	2	4.5
	Piperacillin-tazobactam	≤ 8 - >64	≤ 8	32	11.9
	Ceftazidime	≤ 0.25 - >16	1	16	11.5

1
2
3 **Table 1** (continued)

4
5
6
7

Organism (no. of isolates)	Antimicrobial agent	MIC ($\mu\text{g/mL}$)			% Resistant strains ^b
		Range	50%	90%	
	Cefepime	$\leq 1 - > 16$	≤ 1	8	6.5
	Amikacin	$\leq 4 - > 32$	≤ 4	8	2.0
	Tobramycin	$\leq 2 - > 8$	≤ 2	≤ 2	9.5
	Ciprofloxacin	$\leq 0.25 - > 2$	≤ 0.25	> 2	23.4

8
9
10
11
12
13
14
15
16
17
18

19
20
21 ^a*E. coli*, 153 isolates and *K. pneumoniae*, 48 isolates.

22
23 ^bMICs for resistant isolates are those approved by the EUCAST [11].
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Distribution of doripenem MICs

Organism (no. of isolated tested)	Cumulative % inhibited at MIC ($\mu\text{g/mL}$)								
	≤ 0.06	0.12	0.25	0.5	1	2	4	8	>8
<i>E. coli</i> (153)	88.9	98.0	99.3	100					
<i>K. pneumoniae</i> (48)	50.0	83.3	100						
<i>P. aeruginosa</i> (201)	3.5	10.9	33.8	59.2	80.6	90.5	95.0	99.0	100